Cancer Drug Prices Slashed 96%

The Indian government has taken a significant step in making cancer treatment more affordable by capping trade margins on 137 non-scheduled anti-cancer medicines. As a result, the prices of over 1,000 formulations have been reduced, with some brands seeing price cuts of more than 50%. The highest price reduction is a substantial 96.45%.

The revised prices came into effect on November 9, and the government estimates that this move will lead to annual savings of ₹3,502.31 crore for consumers. This is a significant relief for patients who have been struggling to afford the high costs of cancer treatment.

According to the National Pharmaceutical Pricing Authority (NPPA), 76 pharmaceutical companies have reported revised maximum retail prices (MRPs) for 1,225 formulations covering 121 drugs. Of these, 1,031 formulations have reported price reductions. This indicates that the price cap has had a widespread impact on the pharmaceutical industry.

However, despite the price reduction, access to these medicines remains a challenge for patients in smaller cities. Many patients may still have to travel long distances to access these medicines, which can be a significant burden.

## Why it matters The government's move to cap trade margins on anti-cancer medicines is a crucial step in making cancer treatment more affordable and accessible. Cancer treatment in India has been expensive, and many patients have been unable to afford the high costs. The price reduction is expected to benefit a large number of patients, but the challenge of ensuring access to these medicines in smaller cities remains.

The next step for the government and the pharmaceutical industry is to ensure that these medicines are widely available and accessible to all patients, regardless of their location. This will require efforts to improve the distribution network and make these medicines available in smaller cities and rural areas.